Silvio Danese

224PUBLICATIONS
396CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityPredictive and prognostic markersMajor global burdens of diseaseToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (224)

|Oct 06, 2026
Long-Term Safety of Ontamalimab in Patients with Moderate to Severe Inflammatory Bowel Disease.

|Sep 10, 2026
Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

|Sep 06, 2026
Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real-World Propensity Score-Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup.

|Aug 08, 2026
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression.

|Jul 28, 2026
Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.

|Jul 21, 2026
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial.

Pageof 38

Frequent Collaborators

52 joint publications

Laurent Peyrin-Biroulet

18 joint publications

Sara Massironi

17 joint publications

Ferdinando D'Amico

17 joint publications

Séverine Vermeire